Trans folks: Perrigo updated the FDA drug shortage database today, and have release plans in October and November for 20 and 40 mg/mL doses.
But the drug is already approved and the shortage reason listed is "Inactive Ingredient Shortage". This doesn't require reapproval
-
-
The manufacturer, Luitpold, was approved in 2010, so that's not a barrier either.
Thanks. Twitter will use this to make your timeline better. UndoUndo
-
-
-
Pretty much every article I've read has put the holdup on the FDA due to slow approval after changing manufacturers.
-
The FDA's approval process is more or less predictable, so I don't understand that analysis.
-
The FDA isn't a sudden roadblock, it's a regulatory body with well-documented rules that get followed for every drug.
-
All talk about product being ready to ship and waiting on the FDA.
-
Par changed contract manufacturers and predicted the shortage of this and other drugs in an SEC filing in 2013.
-
But Perrigo didn't comment. Perrigo updated their status today, that's who I'm referring to.
-
I see the update. My problem is this delay isn't seen as critical for approval by the FDA, which is ridiculous.
-
I don't know how to respond to that, other than the FDA doesn't have a pathway for that, really. Blame rests on Par.
- 1 more reply
New conversation -
Loading seems to be taking a while.
Twitter may be over capacity or experiencing a momentary hiccup. Try again or visit Twitter Status for more information.